Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

December 2014

Specialty Pharmacy Program Updates 


Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications for both the Value and Premium formulary:

Name Indication Coverage Available From
Alprolix
(Factor IX) 
Alprolix is the first recombinant, clotting factor IX therapy with prolonged circulation. It is indicated for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia B. Medical Caremark and Accredo
Eloctate
 (Factor VIII)
Eloctate is the first recombinant factor VIII therapy with prolonged circulation.  It is indicated for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A. Medical Caremark and Accredo
Northera (droxidopa) Northera is indicated for the treatment of orthostatic dizziness, lightheadedness or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.  Pharmacy Benefit  Accredo
Zykadia
(ceritinib)
Zykadia is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). Pharmacy Benefit  Accredo

Harvard Pilgrim’s Specialty Pharmacy Program has added the following medication for the Premium only:

Name Indication Coverage Available From
Oralair
(Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) 
Oralair is tablet for sublingual use. This  allergen extract is indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in the product. Pharmacy Benefit  Accredo

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

New Maine Mandate for Oral Chemotherapies

New Version of CAQH Coming in 2015

Medicare Advantage Provider Payments & the Sequestration Reduction

CLINICIAN CORNER

New Quantity Limit for OxyContin

How Care Management Improves Coordination Across Multiple Settings

Specialty Pharmacy Program Updates

Acupuncture Benefit Offered in 2015

Schizophrenia and the Risk of Metabolic Syndrome

PCPs and Behavioral Health Care Providers — Working Together

OFFICE ASSISTANT

Remember to Complete Your Provider Satisfaction Survey

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Contributing Writer

Kristin Edmonston,
Production Coordinator